Therapy Area
Novartis bags paediatric FDA label expansion for Lutathera
Lutathera is approved by the US FDA to treat patients aged 12 years and older with rare gastroenteropancreatic neuroendocrine cancer.
Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint
Ipsen and Skyhawk partner to develop rare neurological therapies
EC approves Pfizer’s Emblaveo for multidrug-resistant infections
Health Canada approves Merck’s Keytruda for gastric cancer treatment
Roche wins second FDA label expansion for Alecensa in NSCLC
